LA JOLLA, Calif., Dec. 10, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Dr. Malath Makhay, Director, Scientific Affairs, presented the poster of MediciNova’s ongoing Phase 2b/3 clinical trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis (ALS) at the 32nd International Symposium on ALS/MND (amyotrophic lateral sclerosis/motor neurone disease) being held virtually on December 7 – 10, 2021.
News
MediciNova to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
LA JOLLA, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova will participate in the virtual Morgan Stanley 19th Annual Global Healthcare Conference which will be held… Click here to view original post… […]
News
MediciNova to Present at the Ladenburg Thalmann 2019 Healthcare Conference in New York
LA JOLLA, Calif., Sept. 11, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the?NASDAQ Global Market?(NASDAQ:MNOV) and the JASDAQ Market of the?Tokyo Stock Exchange?(Code Number: 4875), today announced that?Yuichi Iwa… […]
News
MediciNova to Attend the Morgan Stanley Global Healthcare Conference in New York
LA JOLLA, Calif., Aug. 29, 2019 (GLOBE NEWSWIRE) — MediciNova, Inc., a biopharmaceutical company traded on the?NASDAQ Global Market?(NASDAQ:MNOV) and the JASDAQ Market of the?Tokyo Stock Exchange?(Code Number: 4875), today announced that?MediciNova?… […]
